scholarly journals Role of Recombinant DNA Technology to Improve Life

2016 ◽  
Vol 2016 ◽  
pp. 1-14 ◽  
Author(s):  
Suliman Khan ◽  
Muhammad Wajid Ullah ◽  
Rabeea Siddique ◽  
Ghulam Nabi ◽  
Sehrish Manan ◽  
...  

In the past century, the recombinant DNA technology was just an imagination that desirable characteristics can be improved in the living bodies by controlling the expressions of target genes. However, in recent era, this field has demonstrated unique impacts in bringing advancement in human life. By virtue of this technology, crucial proteins required for health problems and dietary purposes can be produced safely, affordably, and sufficiently. This technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, enhancing food resources, and resistance to divergent adverse environmental effects. Particularly in agriculture, the genetically modified plants have augmented resistance to harmful agents, enhanced product yield, and shown increased adaptability for better survival. Moreover, recombinant pharmaceuticals are now being used confidently and rapidly attaining commercial approvals. Techniques of recombinant DNA technology, gene therapy, and genetic modifications are also widely used for the purpose of bioremediation and treating serious diseases. Due to tremendous advancement and broad range of application in the field of recombinant DNA technology, this review article mainly focuses on its importance and the possible applications in daily life.

1997 ◽  
Vol 78 (s2) ◽  
pp. S125-S133
Author(s):  
Judith Hall

In 1986, in her paper, ‘Animals in the service of human nutrition’, celebrating the award of the E. V. McCollum International Lectureship in Nutrition, Dr Elsie Widdowson observed: ‘Animals have served human nutrition well over the past century.... They are still of great service in human nutrition and may be more essential in the future as proper animal models for human diseases are discovered’. Ten years on, those animal models are an integral part of nutrition research and are providing fundamental tools to study the effects of diet on many of the major diseases of the Western world, including cardiovascular disease, obesity and cancer. Many of these models have been developed through the use of recombinant DNA technology and the expression of normal or mutated genes in the genome of transgenic mice.


Author(s):  
Zumrut Begum Ogel

Rennet, traditionally obtained from calves, is non-vegeterian and unethical due to the slaughter of unweaned animals. Chymosin is highly specific to the Phe105-Met106 bond of κ-casein and has low proteolytic activity. Microbial aspartic proteases can partly replace chymosin. However, recombinant DNA technology has allowed chymosin itself to be produced by bacteria, yeast, and molds. Not only rennet from calf, but from animals like goat kid, lamb, buffalo, camel, and others can be used in cheesemaking. Chymosins of these animals can be cloned and successfully expressed in microorganisms and can be employed in the production of novel as well as traditional cheese products from the milk of camel, goat, and even horse and donkey. This chapter outlines the recombinant DNA techniques applied over the past few years to improve the microbial production of recombinant rennet, from animals and plants.


1986 ◽  
Vol 99 (1) ◽  
pp. 29-37 ◽  
Author(s):  
Matthew D. Scharff ◽  
Ronald A. DePinho ◽  
Samuel Behar ◽  
Cori Beychok ◽  
Seung-Uon Shin ◽  
...  

10.5912/jcb68 ◽  
1969 ◽  
Vol 10 (2) ◽  
Author(s):  
Faiz Kermani ◽  
Pietro Bonacossa

The number of biotechnology compounds has been increasing steadily over the past 20 years, reflecting the key contribution that biotechnology is now making to healthcare. Recombinant DNA technology has been used to develop a number of therapeutic proteins, including antibodies, cytokines, hormones and vaccines for use in tackling and diagnosing a range of disorders. Worldwide there are more than 4,000 specialised biotechnology companies. The most well-known companies are located in the USA and Europe, but there are significant companies emerging in Canada, Australia, New Zealand and throughout Asia – particularly in Japan. Most of these companies are small in size and limited when it comes to finances and this has had an impact on the output of the industry in terms of new drugs.


1992 ◽  
Vol 38 (Special) ◽  
pp. 263-266
Author(s):  
O. IFUKU ◽  
S. HAZE ◽  
J. KISHIMOTO ◽  
M. YANAGI

Sign in / Sign up

Export Citation Format

Share Document